



**George H. Scherr, Ph.D.
33 Monee Road
Park Forest, Illinois 60466
U.S.A.**

Phone: (708)747-3717
Fax: (708)747-3657
E-mail: jir@interaccess.com

7
VCR
8-26 J

**Amended Declaration and Oath for Patent Application
Declaration claiming small entity status (37 CFR 1.9 (f) and 1.27 (b))**

This amended declaration and oath are appended hereto replace the declaration and oath filed with the instant Application Number 09/818,928 on March 28, 2001.

As the below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9 (c) for purposes of paying reduced fees under section 41 (a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled CELLULOSIC FOAM COMPOSITIONS described in the specification filed herewith.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9 (c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9 (d) or a nonprofit organization under 37 CFR 1.9 (e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28 (b))

As the below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled.

CELLULOSIC FOAM COMPOSITIONS

The specification of which is attached hereto.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I do not claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) None

Priority Claimed
NO

I hereby declare that I have prepared, reviewed, and understand the contents of the specification and claims of the application number 09/818,928 as filed with the U.S. Patent Office on March 28, 2001, and that I have prepared, reviewed, and understand the amended claims numbers 78-107 as submitted to the U.S. Patent Office.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

George H. Scherr, Ph.D.

Full name of sole inventor

George H. Scherr

August 8, 2003

Inventor's signature

Date

33 Monee Road, Park Forest, IL 60466

Residence

United States of America

Citizenship

P.O. Box 134, Park Forest, IL 60466

Post Office Address

Phone: (708) 747-3717

Fax: (708) 747-3657

E-mail: jir@interaccess.com


On August 8, 2003, BEFORE ME personally came George H. Scherr

to me known, and known to me to be the individual who executed the foregoing

DECLARATION, and duly acknowledged to me that he executed the same.

Jean M. Jacobs

Notary signature



CURRICULUM VITAE: GEORGE H. SCHERR, Ph.D.

Education:

1937-1941
Queens College, Long Island, N. Y.
Major-Biology; Minor-Chemistry
B.S., June 1941

1946
Princeton University (Extension)
Advanced Organic Chemistry; graduate credit

1948-1951
University of Kentucky, Lexington
Major-Bacteriology; Minor-Cytogenetics
M.S., August, 1949
Ph.D., July 1951

Employment:

1941-1942
New York City Dept. of Health, Social Hygiene Clinic
125 Worth St., N.Y.C., N.Y.
Medical technician and bacteriologist

1942-1943
U.S. Civil Service Commission, AAFTTC, Sioux Falls, S.D.
Senior Instructor, p-2

1943-1944; 1945-1947
American Cyanamid Co., Calco Chemical Division, Bound
Brook, N. J.
Chemist, process development of drugs, dyes, and dye
intermediates.

1944-1945
In service. Animal research division of the Biological
Warfare Service, Camp Detrick, Md.

1948
Nuodex Products Co., Elizabeth, N. J.
Chemist, naphthenic acid products and fungicides

1951-1954
Department of Microbiology, School of Medicine, The
Creighton University, Omaha, Nebraska, Ass't Professor

1954-1959
Dept. of Bacteriology, The University of Illinois,
College of Medicine, Chicago, Ill.
Assoc. Professor - Tenured

1959 - 1969
Director of Research, Colab Laboratories, Inc.
1526 Halsted St., Chicago IL 60411

1969 - 1971
Administrative Research Director, Division of Diagnostics,
Wilson Pharmaceutical Co., 3 Science Rd., Glenwood, IL 60425

1971 - 1982
President and Director of Research, Technam, Inc.
2405 Bond Street, Park Forest South, IL 60466

1973 - 1984
Adjunct Professor, Allied Health Sciences Education
Governors State University, Park Forest South, IL 60466

1978 - 1981
Publisher
Pathotox Publishers, Inc.
2405 Bond Street, Park Forest, IL 60466

1981-1986
President and Director, Testhrix, Inc.
Box 134, Park Forest, IL 60466

1982 - 1984
Consultant Immunologist, Argonne National Laboratory
9700 S. Cass Avenue, Argonne, IL 60439

1990 - 1991
Director of Research
Shepherd Medical Corp.
15 Roth Street
Alexandria, VA 22303

1990 - 1991
Consulting Toxicologist
Illinois State Racehorse Commission
Chicago, IL

1975 - Present
Executive Research Director, American Drug Research Institute (ADRI)
232 Main Street, Park Forest, IL 60466

1981 - Present
Director, CHEM-Orbital
Box 134, Park Forest, IL 60466

GEORGE H. SCHERR

Papers and Publications

*The induction of bacteriophage-resistant mutation of Escherichia coli by carcinogenic agents

Soc. of Amer. Bacteriologists, Abstracts of Papers, 1949
With R. H. Weaver

The induction of bacteriophage-resistant mutation of Escherichia coli by carcinogenic agents

Thesis, University of Kentucky, 1949

* The effect of 9:10-bishydroxymethyl-1:2-benzanthracene and alpha-naphthalene acetic acid on the cell-division mechanism of Saccharomyces cerevisiae

Genetics, 35:690, 1959 (abstract)

A clinical, pathological, and mycological study of fatal case of histoplasmosis in an infant

Mycopathologia et Mycologia Applicata, 6:86-91, 1951
With J.T. McClellan and Margaret Hotchkiss

*Effect of gonadotrophic hormones on systemic moniliasis in mice

Bact. Proceedings, 113, 1951 (abstract)

With R.H. Weaver

An investigation of the therapy of systemic moniliasis in mice ensuing from studies of the dimorphism mechanism in yeasts

Dissertation, University of Kentucky, 1951

*Enhancement of systemic moniliasis in mice by injection of yeast cells

Bact. Proceedings, 113, 1951 (abstract)

With R.H. Weaver

A nephelometric technique for large cultures

Mycologia, 44:575-577, 1952

*A natural mineral medium for the isolation of certain fungi

Bact. Proceedings, 56, 1952 (abstract)

Studies of the dimorphism mechanism in Saccharomyces cerevisiae

Mycopathologia et Mycologia Applicata, 6:182-230, 1952

The effect of environmental temperature on cortisone toxicity for mice

Science, 116:685, 1952

The dimorphism phenomenon in yeasts

Bact. Reviews, 17:51-92, 1953

With R.H. Weaver

The effect of environmental temperature on the course of systemic moniliasis in mice
Mycologia, 45:359-363, 1953

The susceptibility of mice infected with Cryptococcus neoformans encephalomyocarditis (EMC) virus
J. Bact., 65:480-481, 1953

The enhanced dissemination of moniliasis in mice by the injection of yeast cells
J. Creighton Univ. School of Med., 8:20-24, 1953

*The effect of cortisone and somatotrophic hormone (STH) on systemic moniliasis in mice
Proc. Nebraska Acad. Sci., 7. 1953 (abstract)

The use of yeast cells to enhance the virulence of Candida albicans
Mycopathologia et Mycologia Applicata, 6:260-289, 1953

*The effect of cortisone on the course of systemic monillasis in mice
I. The efficacious effect of cortisone for severe infections
Ibid, 6:325-336, 1953

II. An attempt to reverse the toxic affect of cortisone with lowered environmental temperature or somatotrophic hormone (STH)
Ibid, 6:337-353, 1953

Experimental studies on the pathogenesis of encephalomyocarditis (EMC) virus for mice. I. The factor of sex of animal as affecting pathogenicity of inoculum and susceptibility to infection
J. Bact., 66:105-111, 1953

An automatic inoculating instrument
Laboratory Practice, 2:658-659, 1953

Effect of corisone on the course of systemic moniliasis in mice an influence by the severity of infection
Bact. Proceedings, 72, 1953 (abstract)

The factor of sex in thepathogenesis of encephalomyocarditis (EMC) virus for mice
Riassunti delle Comunicazioni, VI Congresso Internazionale di Microbiologia, 11, 102, 1953
Atti del VI Congresso Internazionale di Microbiologia, Roma, Vol. 3, Sez. VIII, pp189-194

The effect of cortisone and somatotrophic hormone on the course of systemic moniliasis in mice
Riassunti delle Comunicazioni, VI Congresso Internazionale di Microbiologia, 111, 44, 1953

The laboratory diagnosis of mycotic infections. 1. Histoplasmosis
Nebraska State Med. J., 39:339-341, 1954

Paper and Publication (cont'd.)

11. Moniliiasis
Ibid., 39:343-346, 1954

The mutagenicity of some carcinogenic compounds for Escherichia coli
Genetics, 39:141-149, 1954
With M. Fishman and R.H. Weaver

The effect of cortisone and somatotrophic hormone on vaccinia
virus lesions and bensyl alcohol toxicity in the embryonated egg
J. Infectious Diseases, 95:160-164, 1954
With J. M. Severens. P. Jurtschuk, jr., and C.L. Wittenberger

A new type of paper impregnated disc for determining microbial
sensitivity to antibiotics and other chemotherapeutic agents
Antibiotics and Chemotherapy, 4:1007-1010, 1954

The therapeutic affect of cortisone, somatotrophic hormone, and
hesperedin methyl chalcone in suppressing experimental moniliiasis
in mice

Mycologia, 47:305-310, 1955

* The reduction of the number and size of vaccinia lesions in
embryonated eggs treated with cortisone and somatotrophic hormone
Bact. Proceedings, M 54, 1954 (abstract)
With J. M. Severens, C.L. Wittenberger, and P. Jurtschuk, Jr.

* The influence of sex hormones, cortisone, and somatotrophin hormone
on systemic moniliiasis in mice
Bact. Proceedings, 86, 1954 (abstract)

* The effect of cortisone, somatotrophin, and vitamin P on moniliiasis
Prod. Nebraska Acad. Sciences, 9, 1954 (abstract)

The therapeutic effectiveness of piromen for experimental moniliiasis
American Inst. of Biological Sci., Bulletin, 59, 1954

A Multi-tipped disc for determining microbial sensitivity to
antibiotics and other chemotherapeutic agents
American Inst. of Biological Sci., Bulletin, 63, 1954

The effect of hormones on experimental moniliiasis in mice. I. Sex
hormones, cortisone, and somatotrophin
Mycopathologia, 8:62-72, 1957

11. Gonadotrophins
Ibid 1, 77-82

Studies on the dimorphism of histoplasma capsulatum I. The roles
of -SH groups and incubation temperature
Experimental Cell Research, 12:92-107, 1957

The therapeutic effectiveness of fungistatic powder for tinea pedis
Illinois Medical J., 112-, 1957

Papers and Publications (con'd)

A new agar for in vitro anti-microbial sensitivity testing
Antibiotics and Chemotherapy, 8:559-606, 1958
With R. M. Bechtle

Induced dimorphism in pathogenic fungi
X Int. congress genetics, Proc, vol II
With J. W. Rippon

The influence of hormones on experimental moniliasis
Monographs on therapy, Squibb Inst. Med. Res., 2:80-82, 1957

Induced dimorphism in dermatophytes
Mycologia, 51:902-914, 1959
With J. W. Rippon

The role of SH-containing compounds in inhibiting the growth of
dimorphic pathogenic fungi
VII International Congress of Microbiology, Stockholm,
April 8, 1958
With V. F. Gerencser

Experimental Histoplasmosis in Cold Blooded Animals
59th Gen. Meeting of S.A.B. St. Louis, Missouri, May 10-16, 1959
With J. W. Rippon

Induced Pathogenicity of Dermatophytes for Deep Organs of Experimental
Animals
59th Gen. Meeting of S.A.B. St. Louis, Missouri, May 10-16, 1959
With J. W. Rippon

Experimental Histoplasmosis in Cold-blooded Animals
Mycopathologia, 11:241-249, 1959
With J. W. Rippon

Studies on Synergists for Antimicrobial Agents
Antibiotics Annual, Medical Encyclopedia, Inc., New York, N. Y.
855-864, 1958-59
With R. M. Bechtle

Studies on Synergists for Antimicrobial Agents. III. Compounds
having plant growth activity
Antibiotics Annual, Medical Encyclopedia, Inc., N. Y.
316-320, 1959-1960

The Potentiation of Antibiotics in the Treatment of Experimental
Infections
Ibid., 321-325, 1959-1960

Studies on Synergists for Antimicrobial Agents. II. Anti-Mycebacterial
agents
Antibiotics and Chemotherapy, 9:715-725, 1959
With R. M. Bechtle

Papers and Publications (cont'd.)

Cellulose acetate electrophoresis in Microbiology and Immunology
Tr. N.Y. Acad. of Sci., 23: 519-530, April, 1961

Use of cellulose acetate strips for electrophoresis if amino acids
Analytical Chem. 34: 777, June, 1962

The Directed isolation of mutants producing increased amounts of
metabolites
Journ. of Applied Bact., 25: 187-194, August, 1962
With M.E. Rafelson (Jr.)

Comparative studies with a new isolation medium for Candida albicans.
Bact. Proceedings, Amer. Soc. for Microbiology, 1962.
With M. Goldin

*A new alginic adjuvant - physical and chemical properties
Bact. Proceedings, Amer. Soc. for Microbiology, 1962

Irreproducible Research
IEEE Transactions on Professional Communication,
Vol. PC-16, No. 3, Sept., 1973

Hemagglutination Inhibition Assay for Gentamicin
Antimicrobial Agents and Chemotherapy, 11/2: 359-361, Feb., 1977

Preparation of a Biologically Stable and Immunogenically Competent
Astatinated Protein
Int. Journ. of Nuclear Med. and Biology, Vol. 4: 219-224, 1977

Hemagglutination Inhibition (chapter of book) Guidelines for Analytical
Toxicology Programs. CRC Press, Inc. Vol. II, 225-233, 1977

*Diagnostic Procedures in Systemic Mycotic Disease
Sixth Annual Post-Graduate Course in Med. Tech.
Royal Inland Hospital, Kamloops, B.C., 1963

Drug Monitoring and Pharmacokinetic Data
With: H.C. Pribor and G. Morrell, Pathotox Pub. 1980

Saccharin - A Report by M.F. Cranmer
Edited, Pathotox Publishers, 1980

A Diagnostic Test for the Dog Heartworm, *Dirofilaria Immitis*
Veterinary and Human Toxicology, Vol. 24, No. 1, February 1982, pp. 1-7

How Many Humans Have Canine Heartworm?
Diagnostic Medicine, May/June 1983
With: Barry A. Scherr, M.D.

Papers and Publications (cont'd.)

Advances in Human Nutrition - Volume 2
With: Edward J. Calabrese, M.D.
Chem-Orbital Publisher, 1985

Advances in Human Nutrition - Volume 3
With: Jon J. Kabara, M.D.
Chem-Orbital Publisher, 1986

Health Effects of Asbestos: Volumes I, II, III
With: Premysl V. Peinhar, M.D.
Chem-Orbital Publisher, 1988

Microbial Cell Division Mechanisms and Related Antibiosis
In: Essays in Microbiology, Ed: Albert Balows,
University of Kentucky Press

Selected Papers From The Journal of Irreproducible Results, 3rd Edition
Edited: George H. Scherr, Ph.D.
Marboro Books Corporation, 1981

The Best of The Journal of Irreproducible Results
Edited: George H. Scherr, Ph.D.
Workman Publishing Company, 1983

Journal Der Unwiederholbaren Experimente
Edited: Dr. George H. Scherr and
Richard Liebmann-Smith
Wolfgang Kruger Verlag, 1983

Journal Der Unwiederholbaren Experimente II
Edited: Dr. George H. Scherr and
Gabriele Herbst,
Barbara Keller,
Heidi Rei
Ernst Guggolz
Wolfgang Kruger Verlag, 1986

Alginates and Alginate Fibers in Clinical Practice
Wounds, Vol 4: 74-80 , 1992

Selected Papers From The Journal of Irreproducible Results
Edited: George H. Scherr and
Jim Glenn
Published by Barnes and Noble, 1997

*Papers presented at international meetings.

Research
Grants-in-aid

Office of Naval Research, Department of the Navy
The effect of Hormones on Experimental Moniliasis
1952-1953
1953-1954 (renewed)

American Academy of Arts and Sciences
The effect of Hormones on Experimental Histoplasmosis
1952-1953

Wyeth Laboratories
Clinical Evaluation of Therapeutic Measures for Dermatophytosis
In collaboration with Dr. Zeno Korth
1952-1953
1953-1954 (renewed)

Wallace and Tiernan
Clinical evaluation of Therapeutic measures for Dermatophytosis
In collaboration with Dr. Z. Korth
1952-1953

American Medical Association
Effect of Hormones on Experimental Histoplasmosis
1952-1953

Investigation of dimorphism in pathogenic fungi
University of Illinois, Graduate Research
1954-1955
1956-1957 (renewed)

N.I.H. (National Institute of Health)
Studies on Dimorphism
1957-1958
1958-1959 (renewed)

Baxter Laboratories
Studies on Chemotherapy
1957-1958
1958-1959 (renewed)

Cook County Tuberculosis Society
Studies on Chemotherapy of Tuberculosis in mice
1959-1960

American Cancer Society Institutional Grant
Studies on cell division and growth
1958-1959
1959-1960 (renewed)

Societies

Past Membership

Genetics Society of America
Society for Industrial Microbiology
Mycological Society of America
International Society for Medical and Veterinary Mycology

Current Membership

Sigma Xi
American Association for the Advancement of Science
Society of American Bacteriologists
New York Academy of Sciences
International Society for Environmental Toxicology and Cancer

Societies - Position Held

Chicago Medical Mycological Society - Past President
Society Industrial Microbiology, Chicago Section - Past Vice-President
American College of Toxicology - Past Secretary

Committees

Chairman
Member
Member

University of Illinois - (1954-1959)

Fellowship Fund Search Committee
Executive Committee of the Graduate Faculty
Committee on Medical Education
for National Defense

Councilor

International Society for Environmental Toxicology and Cancer

Editor

Mycopathologia et Mycologia Applicata
(1953 - 1957)
Journal of Environmental Pathology
and Toxicology
Journal of Irreproducible Results
Journal of Environmental Pathology,
Toxicology and Oncology

Publisher

Journal of Environmental Pathology
and Toxicology
Neurotoxicology
Journal of Irreproducible Results
Journal of Environmental Pathology,
Toxicology and Oncology

Civic

Rotary - Chicago Heights, IL (1955 - 1962)
Park Forest Health Council, Park Forest, Illinois
Member 1955 - 1963

Chairman of the Committee on Chronic Disease Control
Chairman of the Committee on Community Health Planning & Education

PATENTS - GEORGE H. SCHERR

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
1,021,721	Great Britain			Directed Isolation of Mutants
17,969	Israel			Directed Isolation of Mutants
434,569	Switzerland			Directed Isolation of Mutants
3,071,518	USA	1/1/63		Directed Isolation of Mutants
28,197	Great Britain			Specimen & Culture Tube Device
719,959	USA			Specimen & Culture Tube Device
312,937	Sweden	11/6/69	Consolidated Labs	Ovulation Testing
328,718	Sweden	1/7/71	G. H. Scherr	Ovulation Testing
3,436,186	USA	4/1/69	Consolidated Labs	Assessing Ovulation Function
45-28276	Japan			Ovulation
85,507	Mexico	2/16/65	Colab	Ovulation Function
752,975	Italy	3/1/67	Colab	Ovulation
1,431,133	France	1/31/66	Consolidated Labs	Ovulation
1,424,948	France	12/6/65	Colab	Ovulation
454-496	Switzerland	2/16/65	Colab	Ovulation
4,781	Philippines	1/12/70	Colab	Ovulation
140,822	New Zealand	2/17/65	Colab	Ovulation
22,984	Israel	4/30/69	Colab	Ovulation
17,353	Columbia	10/7/69	Colab	Ovulation
22,983	Israel	4/30/69	Colab	Ovulation
140,823	New Zealand	2/17/65	Colab	Ovulation
140,821	New Zealand	2/17/65	Consolidated Labs	Ovulation
28,815	Ireland	2/19/65	G. H. Scherr	Ovulation

PATENTS (CONT'D)

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
461-140	Switzerland	2/16/65	Colab	Ovulation
28,775	Ireland	2/19/65	G. H. Scherr	Ovulation
312,017	Sweden	10/9/69	Colab	Ovulation
15,778	Venezuela	1/4/66	Colab	Ovulation
16,040	Venezuela	4/25/66	Colab	Ovulation
798,245	Canada			Estrindex
798,246	Canada			Estrindex
3,561M	France	10/18/62	Consolidated Labs	New Composition of Vaccines & Antigens
1,505,310	France	10/18/62	Consolidated Labs	Fabrication of New Compositions for Antigens
328,369	Sweden	12/31/70	Consolidated Labs	Fabrication of New Compositions for Antigens
150,892	USA	11/8/61		Parenteral Vaccine & Antigen Composition
3049-P	Argentina			Alginate Vaccine Adjuvant
262,763	Australia			Alginate Vaccine Adjuvant
498,644	Belgium			Alginate Vaccine Adjuvant
737,081	Canada			Alginate Vaccine Adjuvant
103,795	Denmark			Alginate Vaccine Adjuvant
1,170,582	Germany	12/3/64	Consolidated Labs	Alginate Vaccine Adjuvant
950,498	Great Britain			Alginate Vaccine Adjuvant
79,822	India			Alginate Vaccine Adjuvant
18,006	Israel			Alginate Vaccine Adjuvant
470,184	Switzerland			Alginate Vaccine Adjuvant
3,075,883	USA			Alginate Vaccine Adjuvant

PATENTS (CONT'D)

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
2,787,581	USA	4/2/57	G.H. Scherr	Means for Assessing Growth of Microorganisms
2,701,229	USA	2/1/55	G.H. Scherr	Apparatus for Cultivation of Microorganisms
578,055	Canada	6/23/59	G.H. Scherr	Effect of Agents on Growth of Microorganisms
1,171,501	France	10/6/58		Effect of Agents on Growth of Microorganisms
90,498	Denmark	2/12/57		Effect of Agents on Growth of Microorganisms
774,155	Great Britain	5/8/57		Activity of Chemical Compounds/ Microorganisms
2,744,648	USA	5/8/56	G.H. Scherr	Closure (Automatic Inoculating Instrument)
214,180	USA	8/2/62		Culture Medium - Candida Albicans
4,100,268	USA	7/11/78	G.H. Scherr	Detection of Gentamicin
4,096,138	USA	6/20/78	G.H. Scherr	Immunological Test Procedure
3,913,487	USA	10/21/75	G.H. Scherr	Projectile
	USA			Distemper Diagnostic Antigen
1,234,417	United Kingdom	8/15/68	Colab	Electrophoresis Device
695,931	USA			Electrophoresis Device
61,089	Brazil			Multidisk (Sensitivity Testing)
578,055	Canada			Multidisk (Sensitivity Testing)
90,498	Denmark			Multidisk (Sensitivity Testing)
1,171,501	France			Multidisk (Sensitivity Testing)
774,155	Great Britain			Multidisk (Sensitivity Testing)
2,787,581	USA			Multidisk (Sensitivity Testing)
688,595	Canada	6/16/64	G.H. Scherr	Potentiation of Antibiotics

PATENTS (CONT'D)

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Title</u>
35,299/60	England			Potentiation of Antibiotics
3,251,738	USA	5/17/66	G.H. Scherr	Potentiation of Antibiotics
1,513,648	England	6/7/78	G.H. Scherr	Detection of Gentamicin
4,189,466	U. S. A.	2/19/80	G.H. Scherr	Protein A Conjugates
17,036	Columbia	6/3/71	G. H. Scherr	Ovulation
15,901	Columbia	9/27/67	Consolidated Labs	Ovulation Function
727,081	Canada	2/1/66	Consolidated Labs	Parenteral Vaccine & Antigen Composition
659,988	Belgium	2/19/65	Colab	Estrindex
659,987	Belgium	2/19/65	Consolidated Labs	Estrindex
659,989	Belgium	2/19/65	Colab	Estrindex
4,761,281	U.S.A.	8/2/88	G.H. Scherr	Vaccine From Dirofilaria Extracts
5,674,524	U.S.A.	10,07,97	G. H. Scherr	Alginate Fibrous Dressings and Method of Making
5,718,916	U.S.A.	2/17/98	G. H. Scherr	Alginate Foam Products
09/676/670 (App1.)	U.S.A.	filed 4/29/99 Pending	G. H. Scherr	Alginate Foam Compositions
US02/23561	P.C.T.	filed 7/22/02 Pending	G.H. Scherr	Silver Alginate Foam Compositions
09/818928 (App1.)	U.S.A.	filed 8/28/01 Pending	G. H. SCheRr	Cellulosic Foam Compositions
US03/04992 (App1.)	P.C.T.	filed 2/18/03 Pending	G.H. Scherr	Alginate Foam Compositions
09/912,337 (App1.)		7/26/01 accepted to issue	G.H. Scherr	Silver Alginate Foam Compositions

TRADEMARKS - GEORGE H. SCHERR

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Trademark</u>
795,428	USA	9/7/68	Colab	Estrindex
947,620	USA	11/21/72	Blackwell Publications	The Journal of Irreproducible Results
947,621	USA	11/21/72	Blackwell Publications	JIR
144,448	Canada	3/18/66	Consolidated Labs (Canada) Ltd.	Algivant
1,111	Denmark	10/1/70	G. H. Scherr	Estrindex
204,632	Italy	3/12/65	Colab	Estrindex
119,314	Sweden	4/7/67	Colab	Estrindex
12,824	Philippines	5/11/67	Colab	Estrindex
466,904	Spain	2/22/65	Colab	Estrindex
148,148	Canada	11/18/66	Consolidated Labs (Canada) Ltd.	Estrindex
77,569	New Zealand	1/6/65	Colab	Estrindex
151,348	Chili	9/17/65	Colab	Estrindex
54,192	Venezuela	6/5/68	Colab	Estrindex
613,716	USA	10/11/55		Multidisk
717,052	USA	6/20/61		Colab and Design
717,053	USA	6/20/61		Colab
708,611	USA	12/20/60		Fibros
879-880	Ecuador	6/29/66	G. H. Scherr	Multidisk
62,312	Columbia	9/12/66	G. H. Scherr	Multidisk
154,401	Chile	6/20/66	G. H. Scherr	Multidisk
6,699,748	El Salvador	12/7/66	G. H. Scherr	Multidisk
876,984	USA	9/16/69	Colab	Monostat

TRADEMARKS (CONT'D)

<u>Number</u>	<u>Country</u>	<u>Date Issued</u>	<u>Assigned</u>	<u>Trademark</u>
715,160	USA	5/9/61	Consolidated Labs	Calgiswab
75,347	New Zealand	3/9/64	Consolidated Labs	Calgiswab
203,974	Italy	4/5/67	Colab	Calgiswab
	France		Consolidated Labs	Calgiswab
A186,380	Australia	7/6/66	Consolidated Labs	Calgiswab
811,618	USA	7/26/66	Colab	Algivant
902,901	Great Britain	12/13/66	Colab	Algivant
A206,801	Australia	12/12/66	Colab	Algivant
68,067	Ireland	1/6/65	Colab	Estrindex
54,870	Austria	7/1/65	Colab	Estrindex

PRODUCT RESEARCHPRODUCT
MARKETED

Auxotab - entero-identification	Yes
Ovulation Test	Yes
Identification plate for Candida	Yes
Antibiotic Assay Medium	Yes
Blood Agar Base No. 2	Yes
Diagnostic Sensitivity Test Agar Base	Yes
Microbial Transport Media	Yes
1. Modified Stuart's Transport Medium	Yes
2. Urine Transport Medium	Yes
3. Fluid Transport Medium	Yes
4. Viral Transport Medium	Yes
5. Trichomonas Transport & Culture Medium	Yes
Lowenstein-Jensen media	Yes
Dermatophyte Medium	Yes
Acryl Particles	Yes
Dental Calcium Alginate Wool	Yes
Histoplasmosis Latex Antigen	Yes
Rheumatoid Arthritis Latex antigen	Yes
Alginate adjuvant	Yes
Alginate Wool	Yes
Alginate swabs	Yes
Calcium alginate swab in tube	Yes
Infectious Mononucleosis antigen	Yes
Histoplasmosis Latex test	Yes
Polystyrene Latex Particles	Yes
Streptococcus MG agglutination test	Yes
Urethro-genital Calgiswab	Yes
Multidisk sensitivity disk	Yes
Test for Cystic Fibrosis	Yes

PRODUCT RESEARCH (CONT'D)

PRODUCT
MARKETED

Cellulose acetate electrophoresis	Yes
Immuno-diffusion agars	Yes
Cell Press for disrupting microorganisms and tissue cells	Yes
Bacterial sensitivity teaching kit for high schools	Yes
Thin Layer chromatography teaching kit	Yes
Testing for Drugs of Abuse	Yes
Gentamicin detection by H I	No
D. imitis (dog heartworm) diagnostic	Yes
Alginate surgical hemostat	No
Dental hemostat	No
Laser nephelometry reagents	No
Malaria diagnostic	No
Pregnancy test	No
Calcium alginate fiber dressings	Yes
Calcium alginate foam dressings	Yes
Silver alginate foam dressings	Yes